TherapeuticsMD
TXMD
39 hedge funds and large institutions have $7.61M invested in TherapeuticsMD in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
77% more call options, than puts
Call options by funds: $92K | Put options by funds: $52K
8% more funds holding
Funds holding: 36 → 39 (+3)
3.74% more ownership
Funds ownership: 28.24% → 31.98% (+3.7%)
16% less capital invested
Capital invested by funds: $9.02M → $7.61M (-$1.41M)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$315K |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$78K |
| 3 |
CC
Clearline Capital
New York
|
+$26.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$75.5K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$47.2K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$19.5K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.13K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
-$4.83K |
TXMD Hedge Fund Activity: Q4 2023 in Review
39 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2023, worth a combined $7.61M — down 16% from $9.02M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TXMD positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 11 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $315K. The largest seller was Sanders Morris Harris, exiting entirely with an estimated $75.5K sold.
- 39 institutional investors held TherapeuticsMD (TXMD) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $7.61M of TherapeuticsMD stock for Q4 2023, down 16% quarter-over-quarter.
- 6 funds opened new TherapeuticsMD positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest TherapeuticsMD buyer in Q4 2023 was Morgan Stanley, an estimated $315K added.
- The largest TherapeuticsMD seller in Q4 2023 was Sanders Morris Harris, an estimated $75.5K sold.
Based on aggregated 13F filings for Q4 2023.